Get the Stockscreener App
1.57
0.00%
0.00
Femasys Inc stock is traded at $1.57, with a volume of 39,374.
It is up +0.00% in the last 24 hours and up +38.94% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
See More
Previous Close:
$1.57
Open:
$1.55
24h Volume:
39,374
Relative Volume:
0.15
Market Cap:
$35.49M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-1.8916
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
-3.09%
1M Performance:
+38.94%
6M Performance:
+44.04%
1Y Performance:
-16.04%
1-Day Range:
$1.5407
$1.6182
1-Week Range:
$1.52
$1.72
52-Week Range:
$0.86
$2.40
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.57 | 35.49M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
580.00 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
229.56 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.83 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
235.20 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
92.40 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Femasys Inc Stock (FEMY) Latest News
Femasys gains UK approval for women's health products - MSN
Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation - TipRanks
Femasys announces publication of ‘positive’ results from FemBloc trials - TipRanks
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes - StockTitan
Head to Head Survey: Femasys (NASDAQ:FEMY) & Accuray (NASDAQ:ARAY) - Defense World
Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way? - Simply Wall St
FY2024 Earnings Estimate for Femasys Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for Femasys Q1 Earnings? - Defense World
Femasys gains UK approval for women’s health products By Investing.com - Investing.com Nigeria
Femasys Announces UK Regulatory Approvals for FemaSeed® for - GlobeNewswire
Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright - Defense World
Femasys gains UK approval for women's health products By Investing.com - Investing.com Australia
Major Win for Infertility Treatment: Femasys (FEMY) Unlocks UK Market with Triple Product Approval - StockTitan
Head-To-Head Survey: Sonoma Pharmaceuticals (NASDAQ:SNOA) vs. Femasys (NASDAQ:FEMY) - Defense World
Femasys gains approvals for infertility and diagnostic products in Israel - MSN
Pap Test Market: Current Analysis and Forecast (2022-2028) - UnivDatos Market Insights
Femasys Announces Israeli Regulatory Approvals for - GlobeNewswire
Major Win for Women's Health: Femasys Triple-Product Approval Opens New Market - StockTitan
Femasys announces notices of intention to grant for two new European patent applications - MSN
Femasys Announces Notices of Intention to Grant for Two New - GlobeNewswire
Game-Changing Birth Control Tech: Femasys Locks Down Crucial EU Patents for Non-Surgical Alternative - StockTitan
Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed - MSN
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Marketscreener.com
Femasys Announces Notice of Allowance for New U.S. Patent - GlobeNewswire
Femasys Secures Patent Protection for FemaSeed Fertility Treatment Through 2044 - StockTitan
Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC - Defense World
Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next? - Defense World
HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World
Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria
Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports
Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys' FemaSeed Trial Shows Double Pregnancy Success vs Traditional IUI Treatment - StockTitan
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.44%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):